Please login to the form below

Not currently logged in
Email:
Password:

Horizant

This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

FDA blames contract manufacturer delays. Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. ... Then in November 2012, GSK and XenoPort agreed to

Latest news

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... Horizant's approval for the condition was based on two 12-week clinical

  • FDA rejects GSK and Xenoport's Horizant

    GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics